- Home
- NRXS vs DXR Comparison
NRXS vs DXR Comparison
Compare NRXS & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRXS | DXR |
|---|---|---|
| Founded | 2011 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.9M | 71.4M |
| IPO Year | 2023 | 1995 |
Fundamental Metrics
Financial Performance| Metric | NRXS | DXR |
|---|---|---|
| Price | $7.57 | $9.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | ★ 136.6K | 10.6K |
| Earning Date | 05-11-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,569,282.00 | $1,446,345.00 |
| Revenue This Year | $172.91 | $44,935.22 |
| Revenue Next Year | $115.71 | $74.79 |
| P/E Ratio | ★ N/A | $33.83 |
| Revenue Growth | ★ 32.89 | N/A |
| 52 Week Low | $1.94 | $7.10 |
| 52 Week High | $7.97 | $14.76 |
Technical Indicators
Market Signals| Indicator | NRXS | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 59.77 | 53.02 |
| Support Level | $6.58 | $10.00 |
| Resistance Level | $7.85 | $10.49 |
| Average True Range (ATR) | 0.56 | 0.42 |
| MACD | -0.03 | 0.17 |
| Stochastic Oscillator | 75.39 | 99.41 |
Price Performance
Historical ComparisonAbout NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.